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Clinical observations in 70 patients with vitiligo appeared to indicate that S-methoxy-
psoralen (S-MOP) taken orally two to three hours before exposure increased skin tolerance
to ultraviolet radiation. The majority of these patients observed that the normal areas of
their skin were pigmented more intensely than usual and a few stated that the vitiligo
patches showed an increased tolerance to solar radiation. In a previous study oral S-MOP
was reported to decrease the erythema response of patients to artificial ultraviolet light (1).
These two observations (increased tanning ability and increased skin tolerance) have
been studied over the past two years in 21 volunteers with normal skin who received 20—30
mg. of S-MOP two to three hours before exposure to solar radiation in Oregon, California,
Florida, Sun Valley, Idaho and the West Indies. The exposures occurred while the volun-
teers were vacationing or working in the sun and were therefore not controlled. The S-MOP
in this dose was observed to markedly increase tanning in all the volunteers, including
those with a history of poor tanning ability. Increased tolerance to solar exposure was
reported by the subjects who believed they were exposed to an intensity and duration of
sunlight beyond their usual tolerance limit.
To extend these clinical observations a controlled field trial with volunteer subjects
was undertaken in the Arizona desert. Forty-seven healthy, adult males were selected from
among the inmates of the Arizona State Prison at Florence, the sole criterion for selection
being that the subject had a fair and potentially easily burned skin without previous
exposure of the back for at least six months. Half of the subjects randomly allocated were
given capsules containing S-MOP and the other half an identical-appearing placebo capsule.
The identity of the capsules was not revealed, and the contrasting treatments were not de-
coded until after all evaluations of results had been made. A single dose of 50 mg. of S-MOP
was given. This dose was considerably larger than the 20—30 mg. dose previously used in
clinical studies. It was thought that this higher dose level would insure maximum protec-
tion and provide clear-cut results. Three hours after ingestion of the capsules, the subjects
were exposed in the prone position in direct noon-day sunlight. A small (4 inch) diamond-
shaped area of the back was exposed and the shield of heavy white crepe paper was applied
with adhesive tape. The exposure time was 85 minutes.
A second trial was made in which the capsules were switched, so that on each subject
we had a contrast between the effects of the placebo and the S-MOP. The variance between
subjects was considerable, but the crossover design using each subject as his own control
greatly reduced the variance of the difference between the placebo and 8-MOP.
Direct visual readings were made on the exposed areas at 6 hours, 20 hours, 44 hours,
66 hours and one week after exposure. At each reading, ratings were made of erythema,
edema, tenderness, pigmentation, vesicles and scaling on a five point equal interval scale
of 0, 1, 2, 3,4.
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The readings showed significant differences between the placebo and 8-MOP treatments
as follows:
1. Significant differences do not show up until about 44 hours after exposure.
2. At 44 hours post-exposure, erythema and tenderness are significantly greater on the
8-MOP subjects.
3. At one week after exposure the skin responses had disappeared in the placebo group,
except for tanning, but there was significant erythema, edema and tenderness in the
8-MOP group.
A final reading was made at two weeks. On these readings there appeared to be con-
siderably more vesiculation and scaling on the 8-MOP group than with the placebo. No
significant difference in pigmentation was detected between the groups until the two-week
reading. At this time it appeared that the 8-MOP treatment left a deeper residual pigmen-
tation, but it was not possible to evaluate this statistically because of severe sloughing
and consequent depigmentation on 22 of the 47 subjects. Of these depigmeated subjects,
18 showed the depigmentatioa on the 8-MOP areas, and only 4 on the placebo areas. This
difference is significant.
The Arizona field trial provided evidence that 50 mg. 8-MOP taken three hours before
exposure augments all cutaneous responses to solar radiation. In view of the fact that
patients with vitiligo and normal subjects had noted increased tolerance to sunlight and
in order to resolve these conflicting observations, we have carried out a series of field trials
in Oregon during the recent summer months. These trials have been performed at sea level
and on Mt. Hood, and we have used lower doses of the drug in order to approximate our
experiments with the schedules which were used by the vitiligo and normal subjects.
Controlled experiments have been made with 14 normal volunteers using from 10 to 75
mg. 8-MOP taken two to three hours before exposure to solar radiation. Two separate
exposures of previously unirradiated skin were made in the same subject, one without the
Fin. 1. Ingestion of 75 mg. 8-MOP followed by hourly exposures to sunlight. Blistering
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drug (control) and a second exposure two hours after ingestion of 8-MOP. Exposures were
symmetrically spaced around solar noon and equivalent intensities were estimated with
an Epley pyrheliometer. The results indicate that with a dose of 10—30 mg., exposure to
solar radiation for not more than one hour will produce erythema followed by increased
tanning without tenderness or exfoliation. In higher doses the erythema becomes progres-
sively greater with increasing edema followed by exfoliation. Seventy-five mg. 8-MOP
followed by exposure for one hour produced marked tenderness and edema followed by
blistering (Fig. 1).
The augmented tanning response using 8-MOP is demonstrated by the following experi-
ment. Two volunteers were exposed to one hour of solar radiation daily taking 30mg. 8-MOP
two hours before exposure and placebo capsules on alternate days. Each area received a
total of three hours exposure. After six days photographs were made (Fig. 2). The augmen-
tation of tanning witbout other skin changes is clearly apparent by comparing the two
areas of exposure.
From these observations we must conclude that 8-MOP does not have a primary pro-
tective action but rather augments all cutaneous responses. The "protection" reported by
volunteer subjects may be related to the marked increased pigmentation which occurs after
oral use of 8-MOP and repeated daily exposures to ultraviolet radiant energy. Increased
tolerance to sunlight would he especially apparent in those individuals who have a poor
tanning ability and who develop a marked increased tanning response while using 8-MOP.
Thomson (2) has recently emphasized the important role of melanin pigment in the skin as
a protective mechanism against ultraviolet radiation.
Although 8-MOP may have a potential use in increasing skin pigmentation and thus
skin tolerance to sunlight, general use of the drug for this purpose is not recommended at
Fig. 2. Area 124 was exposed for one hour on three separate days two hours after inges-
tion of 30 mg. 8-MOP. Note marked increased tanning without exfoliation. Area 105 was
exposed for one hour on three alternate days while the patient received placebo capsules
two hours before exposure. This area represents the patient's normal tanning response.
8-MOP
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the present time. Further controlled field trials with a larger number of subjects may be
required to detect variations of response between individuals.
We express our gratitude to Warden Eyman of the Arizona State Prison, Florence, Ari-
zona, and to the inmates for their excellent cooperation in the field trial. Dr. Otis Miller,
Tucson, Arizona, gave valuable assistance in the selection of the inmates aud in the grading
of the results.
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